Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort

ObjectiveTo examine the baseline prevalence and longitudinal evolution in non-motor symptoms (NMS) in a prospective cohort of, at baseline, patients with de novo Parkinson’s disease (PD) compared with healthy controls (HC).MethodsParkinson’s Progression Markers Initiative (PPMI) is a longitudinal, o...

Full description

Saved in:
Bibliographic Details
Published inJournal of neurology, neurosurgery and psychiatry Vol. 89; no. 1; pp. 78 - 88
Main Authors Simuni, Tanya, Caspell-Garcia, Chelsea, Coffey, Christopher S, Weintraub, Daniel, Mollenhauer, Brit, Lasch, Shirley, Tanner, Caroline M, Jennings, Danna, Kieburtz, Karl, Chahine, Lana M, Marek, Kenneth
Format Journal Article
LanguageEnglish
Published England BMJ Publishing Group LTD 01.01.2018
BMJ Publishing Group
SeriesResearch paper
Subjects
Age Factors
Amyloid beta-Peptides - cerebrospinal fluid
Amyloid beta-Peptides - genetics
Biomarkers - cerebrospinal fluid
Disease Progression
Early Diagnosis
Female
Humans
Longitudinal Studies
Male
Middle Aged
Movement Disorders
Parkinson Disease - cerebrospinal fluid
Parkinson Disease - diagnosis
Parkinson's disease
Prevalence
Prospective Studies
Severity of Illness Index
Sex Factors
non-motor symptoms
parkinson’s disease
biomarkers
Online AccessGet full text

Cover

Abstract ObjectiveTo examine the baseline prevalence and longitudinal evolution in non-motor symptoms (NMS) in a prospective cohort of, at baseline, patients with de novo Parkinson’s disease (PD) compared with healthy controls (HC).MethodsParkinson’s Progression Markers Initiative (PPMI) is a longitudinal, ongoing, controlled study of de novo PD participants and HC. NMS were rated using the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part I score and other validated NMS scales at baseline and after 2 years. Biological variables included cerebrospinal fluid (CSF) markers and dopamine transporter imaging.Results423 PD subjects and 196 HC were enrolled and followed for 2 years. MDS-UPDRS Part I total mean (SD) scores increased from baseline 5.6 (4.1) to 7.7 (5.0) at year 2 in PD subjects (p<0.001) versus from 2.9 (3.0) to 3.2 (3.0) in HC (p=0.38), with a significant difference between the groups (p<0.001). In the multivariate analysis, higher baseline NMS score was associated with female sex (p=0.008), higher baseline MDS-UPDRS Part II scores (p<0.001) and more severe motor phenotype (p=0.007). Longitudinal increase in NMS severity was associated with the older age (0.008) and lower CSF Aβ1–42 (0.005) at baseline. There was no association with the dose or class of dopaminergic therapy.ConclusionsThis study of NMS in early PD identified clinical and biological variables associated with both baseline burden and predictors of progression. The association of a greater longitudinal increase in NMS with lower baseline Aβ1–42 level is an important finding that will have to be replicated in other cohorts.Trial registrationClinicalTrials.gov identifier: NCT01141023.
AbstractList To examine the baseline prevalence and longitudinal evolution in non-motor symptoms (NMS) in a prospective cohort of, at baseline, patients with de novo Parkinson's disease (PD) compared with healthy controls (HC). Parkinson's Progression Markers Initiative (PPMI) is a longitudinal, ongoing, controlled study of de novo PD participants and HC. NMS were rated using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I score and other validated NMS scales at baseline and after 2 years. Biological variables included cerebrospinal fluid (CSF) markers and dopamine transporter imaging. 423 PD subjects and 196 HC were enrolled and followed for 2 years. MDS-UPDRS Part I total mean (SD) scores increased from baseline 5.6 (4.1) to 7.7 (5.0) at year 2 in PD subjects (p<0.001) versus from 2.9 (3.0) to 3.2 (3.0) in HC (p=0.38), with a significant difference between the groups (p<0.001). In the multivariate analysis, higher baseline NMS score was associated with female sex (p=0.008), higher baseline MDS-UPDRS Part II scores (p<0.001) and more severe motor phenotype (p=0.007). Longitudinal increase in NMS severity was associated with the older age (0.008) and lower CSF Aβ1-42 (0.005) at baseline. There was no association with the dose or class of dopaminergic therapy. This study of NMS in early PD identified clinical and biological variables associated with both baseline burden and predictors of progression. The association of a greater longitudinal increase in NMS with lower baseline Aβ1-42 level is an important finding that will have to be replicated in other cohorts. ClinicalTrials.gov identifier: NCT01141023.
ObjectiveTo examine the baseline prevalence and longitudinal evolution in non-motor symptoms (NMS) in a prospective cohort of, at baseline, patients with de novo Parkinson’s disease (PD) compared with healthy controls (HC).MethodsParkinson’s Progression Markers Initiative (PPMI) is a longitudinal, ongoing, controlled study of de novo PD participants and HC. NMS were rated using the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part I score and other validated NMS scales at baseline and after 2 years. Biological variables included cerebrospinal fluid (CSF) markers and dopamine transporter imaging.Results423 PD subjects and 196 HC were enrolled and followed for 2 years. MDS-UPDRS Part I total mean (SD) scores increased from baseline 5.6 (4.1) to 7.7 (5.0) at year 2 in PD subjects (p<0.001) versus from 2.9 (3.0) to 3.2 (3.0) in HC (p=0.38), with a significant difference between the groups (p<0.001). In the multivariate analysis, higher baseline NMS score was associated with female sex (p=0.008), higher baseline MDS-UPDRS Part II scores (p<0.001) and more severe motor phenotype (p=0.007). Longitudinal increase in NMS severity was associated with the older age (0.008) and lower CSF Aβ1–42 (0.005) at baseline. There was no association with the dose or class of dopaminergic therapy.ConclusionsThis study of NMS in early PD identified clinical and biological variables associated with both baseline burden and predictors of progression. The association of a greater longitudinal increase in NMS with lower baseline Aβ1–42 level is an important finding that will have to be replicated in other cohorts.Trial registrationClinicalTrials.gov identifier: NCT01141023.
To examine the baseline prevalence and longitudinal evolution in non-motor symptoms (NMS) in a prospective cohort of, at baseline, patients with de novo Parkinson's disease (PD) compared with healthy controls (HC).OBJECTIVETo examine the baseline prevalence and longitudinal evolution in non-motor symptoms (NMS) in a prospective cohort of, at baseline, patients with de novo Parkinson's disease (PD) compared with healthy controls (HC).Parkinson's Progression Markers Initiative (PPMI) is a longitudinal, ongoing, controlled study of de novo PD participants and HC. NMS were rated using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I score and other validated NMS scales at baseline and after 2 years. Biological variables included cerebrospinal fluid (CSF) markers and dopamine transporter imaging.METHODSParkinson's Progression Markers Initiative (PPMI) is a longitudinal, ongoing, controlled study of de novo PD participants and HC. NMS were rated using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I score and other validated NMS scales at baseline and after 2 years. Biological variables included cerebrospinal fluid (CSF) markers and dopamine transporter imaging.423 PD subjects and 196 HC were enrolled and followed for 2 years. MDS-UPDRS Part I total mean (SD) scores increased from baseline 5.6 (4.1) to 7.7 (5.0) at year 2 in PD subjects (p<0.001) versus from 2.9 (3.0) to 3.2 (3.0) in HC (p=0.38), with a significant difference between the groups (p<0.001). In the multivariate analysis, higher baseline NMS score was associated with female sex (p=0.008), higher baseline MDS-UPDRS Part II scores (p<0.001) and more severe motor phenotype (p=0.007). Longitudinal increase in NMS severity was associated with the older age (0.008) and lower CSF Aβ1-42 (0.005) at baseline. There was no association with the dose or class of dopaminergic therapy.RESULTS423 PD subjects and 196 HC were enrolled and followed for 2 years. MDS-UPDRS Part I total mean (SD) scores increased from baseline 5.6 (4.1) to 7.7 (5.0) at year 2 in PD subjects (p<0.001) versus from 2.9 (3.0) to 3.2 (3.0) in HC (p=0.38), with a significant difference between the groups (p<0.001). In the multivariate analysis, higher baseline NMS score was associated with female sex (p=0.008), higher baseline MDS-UPDRS Part II scores (p<0.001) and more severe motor phenotype (p=0.007). Longitudinal increase in NMS severity was associated with the older age (0.008) and lower CSF Aβ1-42 (0.005) at baseline. There was no association with the dose or class of dopaminergic therapy.This study of NMS in early PD identified clinical and biological variables associated with both baseline burden and predictors of progression. The association of a greater longitudinal increase in NMS with lower baseline Aβ1-42 level is an important finding that will have to be replicated in other cohorts.CONCLUSIONSThis study of NMS in early PD identified clinical and biological variables associated with both baseline burden and predictors of progression. The association of a greater longitudinal increase in NMS with lower baseline Aβ1-42 level is an important finding that will have to be replicated in other cohorts.ClinicalTrials.gov identifier: NCT01141023.TRIAL REGISTRATIONClinicalTrials.gov identifier: NCT01141023.
Author Jennings, Danna
Kieburtz, Karl
Tanner, Caroline M
Chahine, Lana M
Weintraub, Daniel
Caspell-Garcia, Chelsea
Simuni, Tanya
Mollenhauer, Brit
Coffey, Christopher S
Marek, Kenneth
Lasch, Shirley
AuthorAffiliation 7 Eli Lilly and Company , Indianapolis , Indiana , USA
2 Department of Biostatistics , University of Iowa , Iowa City , Iowa , USA
1 Department of Neurology , Northwestern University Feinberg School of Medicine , Chicago , Illinois , USA
8 University of Rochester Medical Center , Rochester , New York , USA
4 Center of Parkinsonism and Movement Disorders Paracelsus-Elena Klinik Kassel, University Medical Center Goettingen , Kassel , Germany
5 Institute for Neurodegenerative Disorders , New Haven , Connecticut , USA
3 University of Pennsylvania School of Medicine and the Parkinson’s Disease and Mental Illness Research, Education and Clinical Centers (PADRECC and MIRECC), Philadelphia Veterans Affairs Medical Center , Philadelphia , Pennsylvania , USA
9 University of Pennsylvania School of Medicine , Philadelphia , Pennsylvania , USA
6 University of California San Francisco , San Francisco , California , USA
AuthorAffiliation_xml – name: 6 University of California San Francisco , San Francisco , California , USA
– name: 3 University of Pennsylvania School of Medicine and the Parkinson’s Disease and Mental Illness Research, Education and Clinical Centers (PADRECC and MIRECC), Philadelphia Veterans Affairs Medical Center , Philadelphia , Pennsylvania , USA
– name: 9 University of Pennsylvania School of Medicine , Philadelphia , Pennsylvania , USA
– name: 4 Center of Parkinsonism and Movement Disorders Paracelsus-Elena Klinik Kassel, University Medical Center Goettingen , Kassel , Germany
– name: 8 University of Rochester Medical Center , Rochester , New York , USA
– name: 5 Institute for Neurodegenerative Disorders , New Haven , Connecticut , USA
– name: 1 Department of Neurology , Northwestern University Feinberg School of Medicine , Chicago , Illinois , USA
– name: 2 Department of Biostatistics , University of Iowa , Iowa City , Iowa , USA
– name: 7 Eli Lilly and Company , Indianapolis , Indiana , USA
Author_xml – sequence: 1
  givenname: Tanya
  surname: Simuni
  fullname: Simuni, Tanya
  email: tatyana.simuni@nm.org
  organization: Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
– sequence: 2
  givenname: Chelsea
  surname: Caspell-Garcia
  fullname: Caspell-Garcia, Chelsea
  email: tatyana.simuni@nm.org
  organization: Department of Biostatistics, University of Iowa, Iowa City, Iowa, USA
– sequence: 3
  givenname: Christopher S
  surname: Coffey
  fullname: Coffey, Christopher S
  email: tatyana.simuni@nm.org
  organization: Department of Biostatistics, University of Iowa, Iowa City, Iowa, USA
– sequence: 4
  givenname: Daniel
  surname: Weintraub
  fullname: Weintraub, Daniel
  email: tatyana.simuni@nm.org
  organization: University of Pennsylvania School of Medicine and the Parkinson’s Disease and Mental Illness Research, Education and Clinical Centers (PADRECC and MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA
– sequence: 5
  givenname: Brit
  surname: Mollenhauer
  fullname: Mollenhauer, Brit
  email: tatyana.simuni@nm.org
  organization: Center of Parkinsonism and Movement Disorders Paracelsus-Elena Klinik Kassel, University Medical Center Goettingen, Kassel, Germany
– sequence: 6
  givenname: Shirley
  surname: Lasch
  fullname: Lasch, Shirley
  email: tatyana.simuni@nm.org
  organization: Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA
– sequence: 7
  givenname: Caroline M
  surname: Tanner
  fullname: Tanner, Caroline M
  email: tatyana.simuni@nm.org
  organization: University of California San Francisco, San Francisco, California, USA
– sequence: 8
  givenname: Danna
  surname: Jennings
  fullname: Jennings, Danna
  email: tatyana.simuni@nm.org
  organization: Eli Lilly and Company, Indianapolis, Indiana, USA
– sequence: 9
  givenname: Karl
  surname: Kieburtz
  fullname: Kieburtz, Karl
  email: tatyana.simuni@nm.org
  organization: University of Rochester Medical Center, Rochester, New York, USA
– sequence: 10
  givenname: Lana M
  surname: Chahine
  fullname: Chahine, Lana M
  email: tatyana.simuni@nm.org
  organization: University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
– sequence: 11
  givenname: Kenneth
  surname: Marek
  fullname: Marek, Kenneth
  email: tatyana.simuni@nm.org
  organization: Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28986467$$D View this record in MEDLINE/PubMed
BookMark eNqFkU9rFDEchoNU7LZ69yQBL4KM5s9MJuNB0OKfQsUFPXgL2exvulkzyZhkFvbWr9Gv5ycxw9aiPWguOeR53_yS5wQd-eABoceUvKCUi5db78eKEdpWnApG-T20oLWQFefk2xFaEMJYxUlDjtFJSlsyL9k9QMdMdlLUol2g_FYncNYDHiPstANvAGu_xi74S5untfXaYdgFN2UbPA49LjNUQ8gh4rQfxhyGhK3HoKPb46WO361Pwf-8uk54bROU-lc4bwAvl5_OsQmbEPNDdL_XLsGjm_0UfXn_7uvZx-ri84fzszcX1aphIlcGDCNEEMr6xkjJuw6IrE0jTQ1Qnk-MpkQaKrpakFWBO6Ci1502VOqan6LXh9ZxWg2wNuBz1E6N0Q467lXQVv194u1GXYadalrOpGhKwbObghh-TJCyGmwy4Jz2EKakaFfLtmmFEAV9egfdhimWr0uKFUx0oggq1JM_J7od5beOApADYGJIKUJ_i1CiZuNqNq5m4-pgvETEnYixWc-uypus-1fw-SG4Grb_v-YXxiHBAg
CitedBy_id crossref_primary_10_1038_s41531_023_00469_1
crossref_primary_10_1111_ene_14008
crossref_primary_10_3389_fnagi_2023_1133705
crossref_primary_10_1002_mdc3_13122
crossref_primary_10_1016_j_parkreldis_2021_01_004
crossref_primary_10_1007_s40120_021_00246_3
crossref_primary_10_1111_psyg_12489
crossref_primary_10_3233_JPD_191672
crossref_primary_10_3233_JPD_212819
crossref_primary_10_3233_JPD_212936
crossref_primary_10_3233_JPD_225041
crossref_primary_10_3233_JPD_202006
crossref_primary_10_1155_2018_5932028
crossref_primary_10_1038_s41531_024_00714_1
crossref_primary_10_1016_j_msom_2022_10_004
crossref_primary_10_3390_brainsci14040358
crossref_primary_10_1007_s11910_022_01223_5
crossref_primary_10_1038_s41531_021_00207_5
crossref_primary_10_3389_fneur_2024_1395413
crossref_primary_10_1016_j_nbd_2022_105965
crossref_primary_10_14814_phy2_16150
crossref_primary_10_1002_mdc3_14145
crossref_primary_10_3389_fnagi_2023_1240971
crossref_primary_10_1080_14737175_2018_1472578
crossref_primary_10_1177_17562864221150329
crossref_primary_10_3389_fneur_2020_00548
crossref_primary_10_1016_j_nbd_2023_106237
crossref_primary_10_1007_s00415_022_11221_9
crossref_primary_10_1212_WNL_0000000000207077
crossref_primary_10_3389_fneur_2023_1174698
crossref_primary_10_3390_diagnostics11101801
crossref_primary_10_1007_s00415_021_10586_7
crossref_primary_10_1038_s41598_021_94255_9
crossref_primary_10_3390_jpm11070626
crossref_primary_10_1002_ana_25798
crossref_primary_10_1007_s00702_024_02745_7
crossref_primary_10_1016_j_lmot_2022_101847
crossref_primary_10_1016_j_neuropsychologia_2022_108419
crossref_primary_10_1038_s41467_024_48961_3
crossref_primary_10_1038_s41583_021_00542_9
crossref_primary_10_3390_diagnostics11122380
crossref_primary_10_1002_mdc3_13262
crossref_primary_10_1016_j_parkreldis_2024_106001
crossref_primary_10_1038_s41531_023_00505_0
crossref_primary_10_1007_s10072_020_04406_5
crossref_primary_10_1177_1877718X241305711
crossref_primary_10_1016_j_parkreldis_2018_10_018
crossref_primary_10_33590_emj_10314895
crossref_primary_10_1177_08919887211023592
crossref_primary_10_3389_fneur_2023_1155669
crossref_primary_10_1016_j_clineuro_2022_107531
crossref_primary_10_1186_s40035_022_00286_1
crossref_primary_10_3389_fneur_2021_662278
crossref_primary_10_1002_mds_27646
crossref_primary_10_3390_diagnostics12051147
crossref_primary_10_1038_s41598_021_88651_4
crossref_primary_10_3233_JPD_201932
crossref_primary_10_3233_JPD_191856
crossref_primary_10_1042_BST20180467
crossref_primary_10_2174_1570159X20666220315163856
crossref_primary_10_1038_s41591_024_02886_y
crossref_primary_10_1002_mds_29148
crossref_primary_10_1016_j_nrl_2023_02_008
crossref_primary_10_1038_s41531_023_00497_x
crossref_primary_10_1007_s00702_020_02248_1
crossref_primary_10_1002_mds_27361
crossref_primary_10_1016_j_parkreldis_2020_05_016
crossref_primary_10_1016_j_trci_2018_03_008
crossref_primary_10_3389_fneur_2020_610614
crossref_primary_10_1007_s00415_020_09708_4
crossref_primary_10_1111_jan_14476
crossref_primary_10_3233_JPD_212860
crossref_primary_10_1016_j_jns_2019_07_025
crossref_primary_10_1016_j_jagp_2019_03_002
crossref_primary_10_1002_mdc3_12939
crossref_primary_10_1007_s11571_021_09671_4
crossref_primary_10_3389_fresc_2022_952289
crossref_primary_10_3233_JPD_212868
crossref_primary_10_1038_s41537_025_00601_5
crossref_primary_10_1002_mds_29257
crossref_primary_10_1002_cpt_2277
crossref_primary_10_1007_s10339_024_01197_x
crossref_primary_10_1038_s41531_021_00256_w
crossref_primary_10_1002_mds_28763
crossref_primary_10_1007_s00415_020_10140_x
crossref_primary_10_3389_fneur_2022_980935
Cites_doi 10.1002/mds.25383
10.1136/jnnp-2012-303419
10.1007/s00415-013-7085-x
10.1002/mds.26170
10.1007/s00415-016-8384-9
10.1212/WNL.40.10.1529
10.1002/mds.26248
10.1002/mds.26077
10.1007/s00441-004-0956-9
10.1111/j.1532-5415.2005.53221.x
10.1093/sleep/14.6.540
10.1111/ene.12733
10.1111/ene.13106
10.1016/j.pneurobio.2011.09.005
10.1002/mds.25664
10.1212/WNL.57.3.456
10.1002/ana.21291
10.1001/jamaneurol.2013.3861
10.1002/mds.22594
10.1111/ene.13161
10.1001/jamapsychiatry.2014.2476
10.1002/mds.22571
10.1016/j.neurol.2009.09.001
10.1212/WNL.0b013e3182a6cbd5
10.1212/WNL.0000000000002651
10.1111/j.1468-1331.2009.02788.x
10.1002/mds.21740
10.1016/S1474-4422(16)30328-3
10.1136/jnnp-2012-304097
10.1007/s10072-014-1879-1
10.1111/ene.12165
10.1097/01.JGP.0000192488.66049.4b
10.1002/mds.23429
10.1016/j.neulet.2012.11.004
10.1037/0022-006X.44.3.406
10.1016/j.parkreldis.2016.04.001
10.1007/s00415-012-6557-8
10.1371/journal.pone.0175674
10.1016/j.parkreldis.2014.04.023
10.1212/01.wnl.0000183056.89590.0d
10.3233/JPD-150662
10.1001/jamaneurol.2013.2334
10.1288/00005537-198402000-00004
10.1002/mds.22643
10.1002/mds.26510
10.1002/ana.22311
10.1159/000094871
ContentType Journal Article
Copyright Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
2018 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:http://creativecommons.org/licenses/by-nc/4.0
Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. 2018
Copyright_xml – notice: Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
– notice: 2018 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:http://creativecommons.org/licenses/by-nc/4.0
– notice: Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. 2018
DBID 9YT
ACMMV
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7RV
7X7
7XB
88E
88G
88I
8AF
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
BTHHO
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
KB0
M0S
M1P
M2M
M2P
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
7X8
5PM
DOI 10.1136/jnnp-2017-316213
DatabaseName BMJ Open Access Journals
BMJ Journals:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Psychology Database (Alumni)
Science Database (Alumni Edition)
STEM Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
BMJ Journals
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni Edition)
Medical Database
Psychology Database
Science Database
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Psychology
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest AP Science
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Psychology Journals (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
BMJ Journals
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE
ProQuest One Psychology

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: ACMMV
  name: BMJ Journals:Open Access
  url: https://journals.bmj.com/
  sourceTypes: Publisher
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-330X
EndPage 88
ExternalDocumentID PMC5732865
28986467
10_1136_jnnp_2017_316213
jnnp
Genre Multicenter Study
Research Support, Non-U.S. Gov't
Journal Article
Observational Study
GrantInformation_xml – fundername: NINDS NIH HHS
  grantid: U01 NS038529
– fundername: NINDS NIH HHS
  grantid: U01 NS077352
– fundername: NINDS NIH HHS
  grantid: U01 NS079163
– fundername: NINDS NIH HHS
  grantid: U01 NS082329
– fundername: NINDS NIH HHS
  grantid: U01 NS084495
– fundername: NHLBI NIH HHS
  grantid: R01 HL091843
– fundername: NINDS NIH HHS
  grantid: P50 NS053488
– fundername: NINDS NIH HHS
  grantid: U01 NS077108
GroupedDBID ---
.55
.GJ
.VT
0R~
18M
29L
2WC
354
39C
3O-
4.4
40O
41~
53G
5GY
5RE
5VS
7RV
7X7
7~S
88E
88I
8AF
8FI
8FJ
8R4
8R5
9YT
AAHLL
AAKAS
AAOJX
AAUVZ
AAWJN
AAWTL
ABAAH
ABIVO
ABJNI
ABKDF
ABMQD
ABOCM
ABUWG
ABVAJ
ACGFO
ACGFS
ACGOD
ACGTL
ACHTP
ACMFJ
ACMMV
ACOAB
ACOFX
ACQSR
ACTZY
ADBBV
ADCEG
ADFRT
ADUGQ
ADZCM
AEKJL
AENEX
AFKRA
AFWFF
AGQPQ
AHMBA
AHNKE
AHQMW
AI.
AJYBZ
AKKEP
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AZFZN
AZQEC
BAWUL
BENPR
BLJBA
BOMFT
BPHCQ
BTFSW
BTHHO
BVXVI
C45
CAG
CCPQU
COF
CS3
CXRWF
DIK
DU5
DWQXO
E3Z
EBS
EJD
EX3
F5P
FEDTE
FYUFA
GNUQQ
GX1
H13
HAJ
HCIFZ
HMCUK
HVGLF
HYE
HZ~
IAO
IEA
IHR
INH
INR
IOF
IPO
IPY
ITC
J5H
KQ8
L7B
M1P
M2M
M2P
N9A
NAPCQ
NTWIH
NXWIF
O9-
OK1
OMB
OMG
OVD
P2P
PCD
PHGZT
PQQKQ
PROAC
PSQYO
PSYQQ
Q2X
R53
RHI
RMJ
RPM
RV8
SJN
TEORI
TR2
UKHRP
UPT
UYXKK
V24
VH1
VM9
VVN
W8F
WH7
WOW
X7M
YFH
YQT
YQY
ZGI
AAYXX
ACQHZ
ADGHP
AERUA
CITATION
PHGZM
3V.
CGR
CUY
CVF
ECM
EIF
NPM
PKN
RHF
YCJ
7XB
8FK
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
ID FETCH-LOGICAL-b526t-cec2006012f5c88399e084c58c4ee1360ca108c169460bec29e16fa9ac18a43
IEDL.DBID 9YT
ISSN 0022-3050
1468-330X
IngestDate Thu Aug 21 14:30:42 EDT 2025
Fri Jul 11 15:06:12 EDT 2025
Fri Jul 25 03:37:56 EDT 2025
Wed Feb 19 02:35:58 EST 2025
Tue Jul 01 01:21:40 EDT 2025
Thu Apr 24 22:53:35 EDT 2025
Thu Apr 24 23:06:40 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords non-motor symptoms
parkinson’s disease
biomarkers
Language English
License This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0
Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b526t-cec2006012f5c88399e084c58c4ee1360ca108c169460bec29e16fa9ac18a43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
OpenAccessLink http://dx.doi.org/10.1136/jnnp-2017-316213
PMID 28986467
PQID 2194696316
PQPubID 2041879
PageCount 11
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5732865
proquest_miscellaneous_1948757666
proquest_journals_2194696316
pubmed_primary_28986467
crossref_primary_10_1136_jnnp_2017_316213
crossref_citationtrail_10_1136_jnnp_2017_316213
bmj_primary_10_1136_jnnp_2017_316213
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-01-01
PublicationDateYYYYMMDD 2018-01-01
PublicationDate_xml – month: 01
  year: 2018
  text: 2018-01-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
– name: BMA House, Tavistock Square, London, WC1H 9JR
PublicationSeriesTitle Research paper
PublicationTitle Journal of neurology, neurosurgery and psychiatry
PublicationTitleAlternate J Neurol Neurosurg Psychiatry
PublicationYear 2018
Publisher BMJ Publishing Group LTD
BMJ Publishing Group
Publisher_xml – name: BMJ Publishing Group LTD
– name: BMJ Publishing Group
References Mollenhauer, Trautmann, Taylor 2013; 532
Weintraub, Hoops, Shea 2009; 24
Song, Gu, An 2014; 35
Mollenhauer, Trenkwalder, von Ahsen 2006; 22
Marras, Chaudhuri 2016; 31
Stiasny-Kolster, Mayer, Schäfer 2007; 22
Mollenhauer, Trautmann, Sixel-Döring 2013; 81
Erro, Picillo, Vitale 2013; 84
Malek, Swallow, Grosset 2015; 5
Duncan, Khoo, Yarnall 2014; 29
Picillo, Erro, Amboni 2014; 20
Antonini, Barone, Marconi 2012; 259
Martinez-Martin, Chaudhuri, Rojo-Abuin 2015; 22
Compta, Martí, Ibarretxe-Bilbao 2009; 24
Caspell-Garcia, Simuni, Tosun-Turgut 2017; 12
Picillo, Amboni, Erro 2013; 260
Weintraub, Simuni, Caspell-Garcia 2015; 30
Abbott, Petrovitch, White 2001; 57
Doty, Shaman, Kimmelman 1984; 94
Simuni, Caspell-Garcia, Coffey 2015; 30
Barone, Antonini, Colosimo 2009; 24
Weintraub, Oehlberg, Katz 2006; 14
Ju, McLeland, Toedebusch 2013; 70
Tomlinson, Stowe, Patel 2010; 25
Rodriguez-Blazquez, Forjaz, Frades-Payo 2010; 17
Mollenhauer, Zimmermann, Sixel-Döring 2016; 87
Picillo, Nicoletti, Fetoni 2017; 264
Braak, Ghebremedhin, Rüb 2004; 318
Zis, Martinez-Martin, Sauerbier 2015; 22
Kendall, Finch, Auerbach 1976; 44
Nasreddine, Phillips, Bédirian 2005; 53
Picillo, Palladino, Moccia 2016; 27
Pietrzak, Lim, Neumeister 2015; 72
Jankovic, McDermott, Carter 1990; 40
Pont-Sunyer, Hotter, Gaig 2015; 30
Goetz 2010; 166
2011; 95
Shi, Bradner, Hancock 2011; 69
Schrag, Siddiqui, Anastasiou 2017; 16
Ross, Petrovitch, Abbott 2008; 63
Ongre, Larsen, Tysnes 2017; 24
Kang, Irwin, Chen-Plotkin 2013; 70
Johns 1991; 14
Stebbins, Goetz, Burn 2013; 28
Abbott, Ross, White 2005; 65
Erro, Picillo, Vitale 2016; 23
Breen, Williams-Gray, Mason 2013; 84
2020050722275474000_89.1.78.8
2020050722275474000_89.1.78.7
2020050722275474000_89.1.78.4
2020050722275474000_89.1.78.3
Erro (2020050722275474000_89.1.78.9) 2016; 23
2020050722275474000_89.1.78.6
2020050722275474000_89.1.78.5
2020050722275474000_89.1.78.27
2020050722275474000_89.1.78.28
2020050722275474000_89.1.78.2
2020050722275474000_89.1.78.29
2020050722275474000_89.1.78.1
Kang (2020050722275474000_89.1.78.32) 2013; 70
2020050722275474000_89.1.78.31
2020050722275474000_89.1.78.10
2020050722275474000_89.1.78.11
2020050722275474000_89.1.78.33
2020050722275474000_89.1.78.34
Picillo (2020050722275474000_89.1.78.38) 2016; 27
2020050722275474000_89.1.78.13
Picillo (2020050722275474000_89.1.78.37) 2014; 20
Marras (2020050722275474000_89.1.78.16) 2016; 31
Schrag (2020050722275474000_89.1.78.30) 2017; 16
Ongre (2020050722275474000_89.1.78.12) 2017; 24
Zis (2020050722275474000_89.1.78.14) 2015; 22
Simuni (2020050722275474000_89.1.78.45) 2015; 30
Pietrzak (2020050722275474000_89.1.78.46) 2015; 72
Picillo (2020050722275474000_89.1.78.35) 2017; 264
Mollenhauer (2020050722275474000_89.1.78.15) 2016; 87
2020050722275474000_89.1.78.17
2020050722275474000_89.1.78.18
Picillo (2020050722275474000_89.1.78.36) 2013; 260
Rodriguez-Blazquez (2020050722275474000_89.1.78.23) 2010; 17
2020050722275474000_89.1.78.41
2020050722275474000_89.1.78.42
2020050722275474000_89.1.78.21
2020050722275474000_89.1.78.43
2020050722275474000_89.1.78.22
2020050722275474000_89.1.78.44
2020050722275474000_89.1.78.24
2020050722275474000_89.1.78.25
2020050722275474000_89.1.78.47
2020050722275474000_89.1.78.26
Goetz (2020050722275474000_89.1.78.19) 2010; 166
Song (2020050722275474000_89.1.78.39) 2014; 35
Martinez-Martin (2020050722275474000_89.1.78.20) 2015; 22
2020050722275474000_89.1.78.40
References_xml – volume: 28
  start-page: 668
  year: 2013
  article-title: How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: comparison with the unified Parkinson’s disease rating scale
  publication-title: Mov Disord
  doi: 10.1002/mds.25383
– volume: 84
  start-page: 14
  year: 2013
  article-title: Non-motor symptoms in early Parkinson’s disease: a 2-year follow-up study on previously untreated patients
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp-2012-303419
– volume: 260
  start-page: 2849
  year: 2013
  article-title: Gender differences in non-motor symptoms in early, drug naïve Parkinson’s disease
  publication-title: J Neurol
  doi: 10.1007/s00415-013-7085-x
– volume: 30
  start-page: 919
  year: 2015
  article-title: Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson’s disease
  publication-title: Mov Disord
  doi: 10.1002/mds.26170
– volume: 264
  start-page: 1583
  year: 2017
  article-title: The relevance of gender in Parkinson’s disease: a review
  publication-title: J Neurol
  doi: 10.1007/s00415-016-8384-9
– volume: 40
  start-page: 1529
  year: 1990
  article-title: Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson study group
  publication-title: Neurology
  doi: 10.1212/WNL.40.10.1529
– volume: 30
  start-page: 1371
  year: 2015
  article-title: Correlates of excessive daytime sleepiness in de novo Parkinson’s disease: a case control study
  publication-title: Mov Disord
  doi: 10.1002/mds.26248
– volume: 30
  start-page: 229
  year: 2015
  article-title: The onset of nonmotor symptoms in Parkinson’s disease (the ONSET PD study)
  publication-title: Mov Disord
  doi: 10.1002/mds.26077
– volume: 318
  start-page: 121
  year: 2004
  article-title: Stages in the development of Parkinson’s disease-related pathology
  publication-title: Cell Tissue Res
  doi: 10.1007/s00441-004-0956-9
– volume: 53
  start-page: 695
  year: 2005
  article-title: The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
  publication-title: J Am Geriatr Soc
  doi: 10.1111/j.1532-5415.2005.53221.x
– volume: 14
  start-page: 540
  year: 1991
  article-title: A new method for measuring daytime sleepiness: the Epworth sleepiness scale
  publication-title: Sleep
  doi: 10.1093/sleep/14.6.540
– volume: 22
  start-page: 1145
  year: 2015
  article-title: Non-motor symptoms burden in treated and untreated early Parkinson’s disease patients: argument for non-motor subtypes
  publication-title: Eur J Neurol
  doi: 10.1111/ene.12733
– volume: 23
  start-page: 1673
  year: 2016
  article-title: The non-motor side of the honeymoon period of Parkinson’s disease and its relationship with quality of life: a 4-year longitudinal study
  publication-title: Eur J Neurol
  doi: 10.1111/ene.13106
– volume: 95
  start-page: 629
  year: 2011
  article-title: The Parkinson Progression Marker Initiative (PPMI)
  publication-title: Prog Neurobiol
  doi: 10.1016/j.pneurobio.2011.09.005
– volume: 29
  start-page: 195
  year: 2014
  article-title: Health-related quality of life in early Parkinson’s disease: the impact of nonmotor symptoms
  publication-title: Mov Disord
  doi: 10.1002/mds.25664
– volume: 57
  start-page: 456
  year: 2001
  article-title: Frequency of bowel movements and the future risk of Parkinson’s disease
  publication-title: Neurology
  doi: 10.1212/WNL.57.3.456
– volume: 63
  start-page: 167
  year: 2008
  article-title: Association of olfactory dysfunction with risk for future Parkinson’s disease
  publication-title: Ann Neurol
  doi: 10.1002/ana.21291
– volume: 70
  start-page: 1277
  year: 2013
  article-title: Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease
  publication-title: JAMA Neurol
  doi: 10.1001/jamaneurol.2013.3861
– volume: 24
  start-page: 2203
  year: 2009
  article-title: Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson’s disease
  publication-title: Mov Disord
  doi: 10.1002/mds.22594
– volume: 24
  start-page: 105
  year: 2017
  article-title: Fatigue in early Parkinson’s disease: the Norwegian ParkWest study
  publication-title: Eur J Neurol
  doi: 10.1111/ene.13161
– volume: 72
  start-page: 284
  year: 2015
  article-title: Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study
  publication-title: JAMA Psychiatry
  doi: 10.1001/jamapsychiatry.2014.2476
– volume: 24
  start-page: 1461
  year: 2009
  article-title: Validation of the questionnaire for impulsive–compulsive disorders in Parkinson’s disease
  publication-title: Mov Disord
  doi: 10.1002/mds.22571
– volume: 166
  start-page: 1
  year: 2010
  article-title: [Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): a new scale for the evaluation of Parkinson’s disease]
  publication-title: Rev Neurol
  doi: 10.1016/j.neurol.2009.09.001
– volume: 81
  start-page: 1226
  year: 2013
  article-title: Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort
  publication-title: Neurology
  doi: 10.1212/WNL.0b013e3182a6cbd5
– volume: 87
  start-page: 168
  year: 2016
  article-title: Monitoring of 30 marker candidates in early Parkinson disease as progression markers
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000002651
– volume: 17
  start-page: 194
  year: 2010
  article-title: Independent validation of the scales for outcomes in Parkinson’s disease-autonomic (SCOPA-AUT)
  publication-title: Eur J Neurol
  doi: 10.1111/j.1468-1331.2009.02788.x
– volume: 22
  start-page: 2386
  year: 2007
  article-title: The REM sleep behavior disorder screening questionnaire – a new diagnostic instrument
  publication-title: Mov Disord
  doi: 10.1002/mds.21740
– volume: 16
  start-page: 66
  year: 2017
  article-title: Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson’s disease: a cohort study
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(16)30328-3
– volume: 84
  start-page: 233
  year: 2013
  article-title: Excessive daytime sleepiness and its risk factors in incident Parkinson’s disease
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp-2012-304097
– volume: 35
  start-page: 1991
  year: 2014
  article-title: Gender differences on motor and non-motor symptoms of de novo patients with early Parkinson’s disease
  publication-title: Neurol Sci
  doi: 10.1007/s10072-014-1879-1
– volume: 22
  start-page: 37
  year: 2015
  article-title: Assessing the non-motor symptoms of Parkinson’s disease: MDS-UPDRS and NMS Scale
  publication-title: Eur J Neurol
  doi: 10.1111/ene.12165
– volume: 14
  start-page: 169
  year: 2006
  article-title: Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease
  publication-title: Am J Geriatr Psychiatry
  doi: 10.1097/01.JGP.0000192488.66049.4b
– volume: 25
  start-page: 2649
  year: 2010
  article-title: Systematic review of levodopa dose equivalency reporting in Parkinson’s disease
  publication-title: Mov Disord
  doi: 10.1002/mds.23429
– volume: 532
  start-page: 44
  year: 2013
  article-title: Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects
  publication-title: Neurosci Lett
  doi: 10.1016/j.neulet.2012.11.004
– volume: 44
  start-page: 406
  year: 1976
  article-title: The state-trait anxiety inventory: a systematic evaluation
  publication-title: J Consult Clin Psychol
  doi: 10.1037/0022-006X.44.3.406
– volume: 27
  start-page: 89
  year: 2016
  article-title: Gender and non motor fluctuations in Parkinson’s disease: a prospective study
  publication-title: Parkinsonism Relat Disord
  doi: 10.1016/j.parkreldis.2016.04.001
– volume: 259
  start-page: 2621
  year: 2012
  article-title: The progression of non-motor symptoms in Parkinson’s disease and their contribution to motor disability and quality of life
  publication-title: J Neurol
  doi: 10.1007/s00415-012-6557-8
– volume: 12
  year: 2017
  article-title: Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0175674
– volume: 20
  start-page: 850
  year: 2014
  article-title: Gender differences in non-motor symptoms in early Parkinson’s disease: a 2-years follow-up study on previously untreated patients
  publication-title: Parkinsonism Relat Disord
  doi: 10.1016/j.parkreldis.2014.04.023
– volume: 65
  start-page: 1442
  year: 2005
  article-title: Excessive daytime sleepiness and subsequent development of Parkinson disease
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000183056.89590.0d
– volume: 5
  start-page: 947
  year: 2015
  article-title: Tracking Parkinson’s: study design and baseline patient data
  publication-title: J Parkinsons Dis
  doi: 10.3233/JPD-150662
– volume: 70
  start-page: 587
  year: 2013
  article-title: Sleep quality and preclinical Alzheimer disease
  publication-title: JAMA Neurol
  doi: 10.1001/jamaneurol.2013.2334
– volume: 94
  start-page: 176
  year: 1984
  article-title: University of pennsylvania smell identification test: a rapid quantitative olfactory function test for the clinic
  publication-title: Laryngoscope
  doi: 10.1288/00005537-198402000-00004
– volume: 24
  start-page: 1641
  year: 2009
  article-title: The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease
  publication-title: Mov Disord
  doi: 10.1002/mds.22643
– volume: 31
  start-page: 1095
  year: 2016
  article-title: Nonmotor features of Parkinson’s disease subtypes
  publication-title: Mov Disord
  doi: 10.1002/mds.26510
– volume: 69
  start-page: 570
  year: 2011
  article-title: Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
  publication-title: Ann Neurol
  doi: 10.1002/ana.22311
– volume: 22
  start-page: 200
  year: 2006
  article-title: Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson’s disease dementia
  publication-title: Dement Geriatr Cogn Disord
  doi: 10.1159/000094871
– volume: 264
  start-page: 1583
  year: 2017
  ident: 2020050722275474000_89.1.78.35
  article-title: The relevance of gender in Parkinson’s disease: a review
  publication-title: J Neurol
  doi: 10.1007/s00415-016-8384-9
– ident: 2020050722275474000_89.1.78.7
  doi: 10.1007/s00415-012-6557-8
– ident: 2020050722275474000_89.1.78.33
  doi: 10.1002/mds.23429
– ident: 2020050722275474000_89.1.78.3
  doi: 10.1212/WNL.57.3.456
– ident: 2020050722275474000_89.1.78.5
  doi: 10.1002/mds.26077
– volume: 24
  start-page: 105
  year: 2017
  ident: 2020050722275474000_89.1.78.12
  article-title: Fatigue in early Parkinson’s disease: the Norwegian ParkWest study
  publication-title: Eur J Neurol
  doi: 10.1111/ene.13161
– ident: 2020050722275474000_89.1.78.40
  doi: 10.1212/WNL.40.10.1529
– ident: 2020050722275474000_89.1.78.28
  doi: 10.1288/00005537-198402000-00004
– ident: 2020050722275474000_89.1.78.44
  doi: 10.1002/ana.22311
– volume: 16
  start-page: 66
  year: 2017
  ident: 2020050722275474000_89.1.78.30
  article-title: Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson’s disease: a cohort study
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(16)30328-3
– ident: 2020050722275474000_89.1.78.47
  doi: 10.1001/jamaneurol.2013.2334
– volume: 22
  start-page: 1145
  year: 2015
  ident: 2020050722275474000_89.1.78.14
  article-title: Non-motor symptoms burden in treated and untreated early Parkinson’s disease patients: argument for non-motor subtypes
  publication-title: Eur J Neurol
  doi: 10.1111/ene.12733
– ident: 2020050722275474000_89.1.78.43
  doi: 10.1002/mds.22594
– volume: 30
  start-page: 1371
  year: 2015
  ident: 2020050722275474000_89.1.78.45
  article-title: Correlates of excessive daytime sleepiness in de novo Parkinson’s disease: a case control study
  publication-title: Mov Disord
  doi: 10.1002/mds.26248
– ident: 2020050722275474000_89.1.78.17
  doi: 10.1016/j.pneurobio.2011.09.005
– volume: 166
  start-page: 1
  year: 2010
  ident: 2020050722275474000_89.1.78.19
  article-title: [Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): a new scale for the evaluation of Parkinson’s disease]
  publication-title: Rev Neurol
  doi: 10.1016/j.neurol.2009.09.001
– ident: 2020050722275474000_89.1.78.25
  doi: 10.1002/mds.22571
– ident: 2020050722275474000_89.1.78.24
  doi: 10.1037/0022-006X.44.3.406
– volume: 260
  start-page: 2849
  year: 2013
  ident: 2020050722275474000_89.1.78.36
  article-title: Gender differences in non-motor symptoms in early, drug naïve Parkinson’s disease
  publication-title: J Neurol
  doi: 10.1007/s00415-013-7085-x
– volume: 70
  start-page: 1277
  year: 2013
  ident: 2020050722275474000_89.1.78.32
  article-title: Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease
  publication-title: JAMA Neurol
– volume: 87
  start-page: 168
  year: 2016
  ident: 2020050722275474000_89.1.78.15
  article-title: Monitoring of 30 marker candidates in early Parkinson disease as progression markers
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000002651
– volume: 17
  start-page: 194
  year: 2010
  ident: 2020050722275474000_89.1.78.23
  article-title: Independent validation of the scales for outcomes in Parkinson’s disease-autonomic (SCOPA-AUT)
  publication-title: Eur J Neurol
  doi: 10.1111/j.1468-1331.2009.02788.x
– ident: 2020050722275474000_89.1.78.21
  doi: 10.1111/j.1532-5415.2005.53221.x
– ident: 2020050722275474000_89.1.78.22
  doi: 10.1097/01.JGP.0000192488.66049.4b
– volume: 23
  start-page: 1673
  year: 2016
  ident: 2020050722275474000_89.1.78.9
  article-title: The non-motor side of the honeymoon period of Parkinson’s disease and its relationship with quality of life: a 4-year longitudinal study
  publication-title: Eur J Neurol
  doi: 10.1111/ene.13106
– ident: 2020050722275474000_89.1.78.18
  doi: 10.3233/JPD-150662
– ident: 2020050722275474000_89.1.78.29
  doi: 10.1002/mds.26170
– ident: 2020050722275474000_89.1.78.27
  doi: 10.1002/mds.21740
– volume: 27
  start-page: 89
  year: 2016
  ident: 2020050722275474000_89.1.78.38
  article-title: Gender and non motor fluctuations in Parkinson’s disease: a prospective study
  publication-title: Parkinsonism Relat Disord
  doi: 10.1016/j.parkreldis.2016.04.001
– ident: 2020050722275474000_89.1.78.13
  doi: 10.1136/jnnp-2012-303419
– volume: 20
  start-page: 850
  year: 2014
  ident: 2020050722275474000_89.1.78.37
  article-title: Gender differences in non-motor symptoms in early Parkinson’s disease: a 2-years follow-up study on previously untreated patients
  publication-title: Parkinsonism Relat Disord
  doi: 10.1016/j.parkreldis.2014.04.023
– volume: 72
  start-page: 284
  year: 2015
  ident: 2020050722275474000_89.1.78.46
  article-title: Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study
  publication-title: JAMA Psychiatry
  doi: 10.1001/jamapsychiatry.2014.2476
– ident: 2020050722275474000_89.1.78.31
  doi: 10.1002/mds.25383
– ident: 2020050722275474000_89.1.78.2
  doi: 10.1136/jnnp-2012-304097
– ident: 2020050722275474000_89.1.78.8
  doi: 10.1002/mds.22643
– ident: 2020050722275474000_89.1.78.26
  doi: 10.1093/sleep/14.6.540
– ident: 2020050722275474000_89.1.78.41
  doi: 10.1159/000094871
– volume: 31
  start-page: 1095
  year: 2016
  ident: 2020050722275474000_89.1.78.16
  article-title: Nonmotor features of Parkinson’s disease subtypes
  publication-title: Mov Disord
  doi: 10.1002/mds.26510
– volume: 35
  start-page: 1991
  year: 2014
  ident: 2020050722275474000_89.1.78.39
  article-title: Gender differences on motor and non-motor symptoms of de novo patients with early Parkinson’s disease
  publication-title: Neurol Sci
  doi: 10.1007/s10072-014-1879-1
– ident: 2020050722275474000_89.1.78.42
  doi: 10.1016/j.neulet.2012.11.004
– volume: 22
  start-page: 37
  year: 2015
  ident: 2020050722275474000_89.1.78.20
  article-title: Assessing the non-motor symptoms of Parkinson’s disease: MDS-UPDRS and NMS Scale
  publication-title: Eur J Neurol
  doi: 10.1111/ene.12165
– ident: 2020050722275474000_89.1.78.1
  doi: 10.1212/01.wnl.0000183056.89590.0d
– ident: 2020050722275474000_89.1.78.6
  doi: 10.1007/s00441-004-0956-9
– ident: 2020050722275474000_89.1.78.34
  doi: 10.1371/journal.pone.0175674
– ident: 2020050722275474000_89.1.78.10
  doi: 10.1002/mds.25664
– ident: 2020050722275474000_89.1.78.11
  doi: 10.1212/WNL.0b013e3182a6cbd5
– ident: 2020050722275474000_89.1.78.4
  doi: 10.1002/ana.21291
SSID ssj0000089
Score 2.5356147
Snippet ObjectiveTo examine the baseline prevalence and longitudinal evolution in non-motor symptoms (NMS) in a prospective cohort of, at baseline, patients with de...
To examine the baseline prevalence and longitudinal evolution in non-motor symptoms (NMS) in a prospective cohort of, at baseline, patients with de novo...
SourceID pubmedcentral
proquest
pubmed
crossref
bmj
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 78
SubjectTerms Age Factors
Amyloid beta-Peptides - cerebrospinal fluid
Amyloid beta-Peptides - genetics
Biomarkers - cerebrospinal fluid
Disease Progression
Early Diagnosis
Female
Humans
Longitudinal Studies
Male
Middle Aged
Movement Disorders
Parkinson Disease - cerebrospinal fluid
Parkinson Disease - diagnosis
Parkinson's disease
Prevalence
Prospective Studies
Severity of Illness Index
Sex Factors
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Nb9QwELWgSIgL4ptAQUbqhUO0cWI7Xi4IEFVBWlQJkPZmOY4tWnWTsMlW6o2_wd_jlzDjeEMXpHKOnTh-M_bYY79HyIHljinvwdM84ykva54ajgdsuGKGZaayQSVi8UkefeUfl2IZN9z6eKxyOyaGgbpuLe6Rz8CzYCUnCyZfd99TVI3C7GqU0LhObiB1GR7pKpflpfBXzSe28Exk2zRlIWenTdOBhTDcpJN5EDeoVqe7k9M_EeffBycvzUSHd8jtGELSNyPmd8k119wjNxcxSX6fDG9NuGXuaLdGMm_0XWqamp61KE60qVEIi7rzaHS09bRpmxQwa9e0v1h1Q7vq6UlDHZIfU7wXHa6I_frxs6cxofOKQuBIj48XHyhK7K6HB-Tz4fsv747SKK6QViKXQ2qdzQMZS-6FVRAmzV2muBUK0HPQQ5kFqJRlEro9A6DzuWPSm7mxTBlePCR70DT3mFCfM1_7XNSFyrh33FQQMRROlnWdicpWCTmAntXdSJ6hw6KjkBoB0AiAHgFIyGzb9dpGenJUyTi7osbLqcb_376_RVNHJ-31H5NKyIvpMbgX5kxM49pNr6EIUv7DIi8hj0bwp4_BWlVJmGgSUu6YxVQAqbt3nzQn3wKFt0COJCmeXN2sp-QW_IMad3z2yd6w3rhnEAMN1fNg6L8Bq30GaA
  priority: 102
  providerName: ProQuest
Title Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort
URI https://jnnp.bmj.com/content/89/1/78.full
https://www.ncbi.nlm.nih.gov/pubmed/28986467
https://www.proquest.com/docview/2194696316
https://www.proquest.com/docview/1948757666
https://pubmed.ncbi.nlm.nih.gov/PMC5732865
Volume 89
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwELZoKyEuiH8CZWWkXjhEjRPbcbi1VauClGoFBS0ny3Fs0aqbrDZZJG68Bq_HkzCTZEO3IOAURf5JNN-MPfbY3xCyZ7ljynuwNM94yNOSh4bjARuumGGRKWyXJSI_k6cf-NuZmP2iybkRwWeJ3L-sqgVgyXA7TcaYoHano2RBbf50fs3VVdnIDB6JaB2S_EMPSACskJYck8tvFfPLzTnpN0fz5nnJaxPQyT1yd_Ac6UEP9X1yy1UPyO18iI0_JO2h6S6XO7pYIoc3miw1VUmvasxJtCox_xV1XwZdo7WnsPQPAap6SZuv80Vbzxt6UVGHnMcUr0N3N8N-fPve0CGO85qCv0in0_wNxcy6y_YReX9yfH50Gg45FcJCxLINrbNxx8ESe2EVeEeZixS3QgFoDoQVWUBIWSYzLiPAN84ck95kxjJlePKYbMOvuaeE-pj50seiTFTEveOmAEchcTIty0gUtgjIHkhWL3rODN2tNRKpEQuNWOgei4Dsr0Wv7cBKjskxrv7S4tXY4t-9767R1INtNhrGaC5h3GEyIC_HYrAqDJWYytWrRkMVZPqHtV1AnvTgjx9b605A0g21GCsgY_dmSXXxuWPuFkiNJMWz_5PNc3IH3lS_4bNLttvlyr0AF6gtJmQrnaWTzgImZOfgKM8_wvPw-Gz67ifBPwOo
linkProvider BMJ Publishing Group Ltd
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELZKKwEXxD-BAkYqBw7Rxonj9SIhRKHVLu2uVlCknmo5ji1adZOwyYJ64zV4B56KJ2EmP0sXpHLqOY7_Zjye8djfR8iW4ZZJ52ClOcZ93k-5rzlesOGSaRboxNQsEeOJGH7i7w_jwzXys3sLg9cqO5tYG-o0N3hG3oOVBZGciJh4XXzxkTUKs6sdhUajFnv27BuEbOWr0TuQ7_Mw3N05eDv0W1YBP4lDUfnGmrBGIQldbCT4BwMbSG5iCd22LBKBgT5KwwS0F8AIw4FlwumBNkxqHkGtV8gGh3JgBja2dybTD-fcbTlYopMHcdClRSPRO8myAjSS4aGgCGsyhWR2sroZ_uPh_n1R89zOt3uT3GhdVvqm0bFbZM1mt8nVcZuUv0OqbV2_are0mCN4ONoKqrOUnuZIhrRIkXiL2q-tktPc0SzPfNCRfE7Ls1lR5bOSHmfUItgyxXfY9ZO0X99_lLRNIL2k4KjS6XQ8okjpO6_uko-XMO33yDp0zT4g1IXMpS6M00gG3FmuE_BQIiv6aRrEiUk8sgUzq4oGrEPVQU4kFApAoQBUIwCP9LqpV6aFQ0dWjtML_nix_OP_tW920lStUSjVHxX2yLPlZ1jOmKPRmc0XpYIiSDEAQaVH7jfCXzYGsbEUsLF5pL-iFssCCBW--iU7_lxDhseIySTihxd36ym5NjwY76v90WTvEbkO45HNadMmWa_mC_sY_K8qedKqPSVHl7vOfgNM_kLD
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELZKkSouiH9CCxipHDhEGyeO40VCCCirLmWrlQBpT1iOY4tW3STdZEG98Rq8Cc_DkzCTn6ULUjn1HMd_M2PPeOzvI2TXcMukc2BpjnGfJxn3NccLNlwyzQKdmoYlYnIo9j_xd7N4tkF-9m9h8FplvyY2C3VWGDwjH4BlQSQnIiYGrrsWMd0bvSxPfWSQwkxrT6fRqsiBPfsG4Vv1YrwHsn4ahqO3H9_s-x3DgJ_Goah9Y03YIJKELjYSfIWhDSQ3sYQhWBaJwEB_pWEC2g5gtOHQMuH0UBsmNY-g1ivkahLFDC0smSXnHG85XOGUB3HQJ0gjMTjO8xJ0k-HxoAgbWoV0fry-Lf7j6_59ZfPcHji6Qa53zit91WrbTbJh81tka9Kl52-T-rVu3rdbWi4QRhxXDarzjJ4USIu0zJCCi9qvnbrTwtG8yH3QlmJBq7N5WRfzih7l1CLsMsUX2c3jtF_ff1S0SyU9p-Cy0ul0MqZI7ruo75APlzDpd8kmdM3eJ9SFzGUujLNIBtxZrlPwVSIrkiwL4tSkHtmFmVVlC9uhmnAnEgoFoFAAqhWARwb91CvTAaMjP8fJBX88W_3x_9p3emmqbnmo1B9l9siT1WcwbMzW6NwWy0pBESQbgPDSI_da4a8agyhZCtjiPJKsqcWqAIKGr3_Jj7404OExojOJ-MHF3XpMtsC61Pvx4cE2uQbDke2x0w7ZrBdL-xAcsTp91Og8JZ8v18R-A7j-RZM
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Baseline+prevalence+and+longitudinal+evolution+of+non-motor+symptoms+in+early+Parkinson%E2%80%99s+disease%3A+the+PPMI+cohort&rft.jtitle=Journal+of+neurology%2C+neurosurgery+and+psychiatry&rft.au=Simuni%2C+Tanya&rft.au=Caspell-Garcia%2C+Chelsea&rft.au=Coffey%2C+Christopher+S&rft.au=Weintraub%2C+Daniel&rft.date=2018-01-01&rft.pub=BMJ+Publishing+Group+LTD&rft.issn=0022-3050&rft.eissn=1468-330X&rft.volume=89&rft.issue=1&rft.spage=78&rft_id=info:doi/10.1136%2Fjnnp-2017-316213&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3050&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3050&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3050&client=summon